Tulane scientists found that an FDA-approved cancer drug may help the immune system clear out damaged cells that cause lung ...

Roughly one in five (21 percent) of idiopathic pulmonary ... from people affected by chronic ... Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF ... many respiratory conditions with clear causes, IPF remains shrouded in mystery ...

There are several different types/causes of pulmonary fibrosis and are difficult to diagnose and treat ... The UAB ILD Center offers clinical trial enrollment for patients with idiopathic pulmonary ...

R&D, strategic partnerships, and rising IPF cases, leading to innovative therapies and improved patient outcomes ...

Researchers reveal critical mechanism behind idiopathic pulmonary fibrosis. Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease ...

Shionogi and InterMune have announced the marketing approval of pirfenidone (Pirespa) for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan, making it the first approved therapy for ...

First-ever use of Ebenbuild's Twinhale technology  in idiopathic pulmonary fibrosis lung modelsTrial results published in Nature Communications Munich, Germany - April 9, 2025 -- Ebenbuild, a company ...

highlights the potential of inhaled therapeutics for treating idiopathic pulmonary fibrosis (IPF), a devastating lung disease with limited treatment options. Ebenbuild’s advanced digital lung ...